Skip to Content

Ceftolozane / tazobactam Pregnancy and Breastfeeding Warnings

Ceftolozane / tazobactam is also known as: Zerbaxa

Ceftolozane / tazobactam Pregnancy Warnings

Animal studies with IV ceftolozane have failed to reveal evidence of fetal harm at exposures up to 7 (mice) and 4 (rats) times the daily human exposure in healthy adults (at clinical dose of 1 g 3 times a day). Animal studies with IV tazobactam have revealed evidence of maternal toxicity but have failed to reveal evidence of fetal toxicity; in rats, maternal toxicity (decreased food intake and body weight gain) was observed at exposures about 19 times the recommended human dose (based on body surface area). It is not known if ceftolozane crosses the placenta in animals; tazobactam was shown to cross the placenta in rats and reach levels in the fetus up to 10% of those found in maternal plasma. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: B1
US FDA pregnancy category: B

See references

Ceftolozane / tazobactam Breastfeeding Warnings

LactMed: Use is considered acceptable.
-According to some authorities: The benefit should outweigh the risk to the mother and infant; caution is recommended.
-According to some authorities: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother and the benefit of breastfeeding for the infant.

Excreted into human milk: Unknown (ceftolozane, tazobactam)
Excreted into animal milk: Data not available (ceftolozane, tazobactam)

Comments:
-The effects in the nursing infant are unknown.
-No data available on the clinical use of this drug during breastfeeding; no serious side effects reported for other cephalosporins during breastfeeding.
-Disruption of infant's gastrointestinal flora (resulting in diarrhea or thrush) reported occasionally with cephalosporins; such effects have not been adequately evaluated.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Zerbaxa (ceftolozane-tazobactam)." Cubist Pharmaceuticals Inc, Lexington, MA.

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Zerbaxa (ceftolozane-tazobactam)." Cubist Pharmaceuticals Inc, Lexington, MA.
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide